Topical "Botox"--Sounds Like a Winner

Implications: It is not unexpected that Medicis is expanding into the "Botox" business since its rival company, Allergan, has a monopoly on the market.  Allergan also has Juviderm, which competes directly with Restylane, the hit product by Medicis.  This will place Medicis back into the competitive market place.

Analysis: The cosmetic market place has been in flux over the past few years.  The big player, Allergan, is the sole producer of Botox in the United States and thus has a corner on the market place.  They also have a very popular injectable hyaluronic acid product, Juviderm, which competes directly with Restylane from Medicis.  By acquiring this company, Medicis can try to level the playing field with Allergan.  Also, if a topical Botulinum Toxin proves to be effective, it may revolutionize the industry.  I also think this will benefit the patient financially since Allergan will no longer have a monopoly.

Submitted by,

Alan Zaccaria, MD